Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 51.09% is 702% above its 5-year average of -8.49%, near the high end of its 5-year range (-52.22%–52.54%).
As of the fiscal period ended Tuesday, June 30, 2026. 32.77% above its 12-month average of 38.48%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 51.09%.
RETURN ON EQUITY (ROE)
51.09%
RETURN ON EQUITY (ROE) AVG TTM
38.48%
RETURN ON EQUITY (ROE) AVG 3Y
8.41%
RETURN ON EQUITY (ROE) AVG 5Y
-8.49%
RETURN ON EQUITY (ROE) AVG 10Y
-32.61%
RETURN ON EQUITY (ROE) AVG 15Y
-36.10%
RETURN ON EQUITY (ROE) AVG 20Y
-46.12%
CURRENT VS TTM AVG
+32.77%
CURRENT VS 3Y AVG
+507.13%
CURRENT VS 5Y AVG
+701.75%
CURRENT VS 10Y AVG
+256.66%
CURRENT VS 15Y AVG
+241.51%
CURRENT VS 20Y AVG
+210.76%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+221.61%
vs the sector median at left
Aurinia Pharmaceuticals Inc.
Market Cap
$2.02B
Return on Equity (ROE)
51.09%
TTM Avg
38.48%
3Y Avg
8.41%
5Y Avg
-8.49%
Market Cap
$2.02B
Return on Equity (ROE)
N/A
TTM Avg
793.39%
3Y Avg
466.61%
5Y Avg
69.31%
Market Cap
$2.02B
Return on Equity (ROE)
N/A
TTM Avg
-101.38%
3Y Avg
-17.29%
5Y Avg
175.33%
Market Cap
$2.03B
Return on Equity (ROE)
17.35%
TTM Avg
12.11%
3Y Avg
10.87%
5Y Avg
16.24%
Market Cap
$2.05B
Return on Equity (ROE)
6.55%
TTM Avg
4.11%
3Y Avg
-0.47%
5Y Avg
-0.69%
Market Cap
$1.98B
Return on Equity (ROE)
-16.25%
TTM Avg
-99.56%
3Y Avg
-48.75%
5Y Avg
-32.00%
Market Cap
$2.06B
Return on Equity (ROE)
-42.07%
TTM Avg
-35.11%
3Y Avg
-34.40%
5Y Avg
-30.49%
Market Cap
$1.97B
Return on Equity (ROE)
16.36%
TTM Avg
13.19%
3Y Avg
3.41%
5Y Avg
-4.94%
Market Cap
$2.06B
Return on Equity (ROE)
-58.45%
TTM Avg
-43.81%
3Y Avg
-43.57%
5Y Avg
-51.47%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.02B | 51.09% | 38.48% | 8.41% | -8.49% |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | N/A | 793.39% | 466.61% | 69.31% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A | -101.38% | -17.29% | 175.33% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 17.35% | 12.11% | 10.87% | 16.24% |
| Vericel Corporation (VCEL)vs › | $2.05B | 6.55% | 4.11% | -0.47% | -0.69% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | -16.25% | -99.56% | -48.75% | -32.00% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -42.07% | -35.11% | -34.40% | -30.49% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 16.36% | 13.19% | 3.41% | -4.94% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -58.45% | -43.81% | -43.57% | -51.47% |
| Alvotech (ALVO)vs › | $2.08B | N/A | 23.18% | 49.13% | 48.50% |
ROE
51.1%
ROA
39.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 51.09% |
| 2026-03-31 | 52.54% |
| 2025-12-31 | 49.40% |
| 2025-09-30 | 21.28% |
| 2025-06-30 | 18.08% |
| 2025-03-31 | 11.38% |
| 2024-12-31 | 1.52% |
| 2024-09-30 | -5.81% |
| 2024-06-30 | -13.81% |
| 2024-03-31 | -17.40% |
| 2023-12-31 | -20.64% |
| 2023-09-30 | -19.70% |
| 2023-06-30 | -18.54% |
| 2023-03-31 | -24.78% |
| 2022-12-31 | -26.68% |
| 2022-09-30 | -27.27% |
| 2022-06-30 | -36.98% |
| 2022-03-31 | -37.54% |
| 2021-12-31 | -37.77% |
| 2021-09-30 | -52.22% |
| 2021-06-30 | -44.42% |
| 2021-03-31 | -34.34% |
| 2020-12-31 | -25.18% |
| 2020-09-30 | -42.90% |
| 2020-06-30 | -61.91% |
| 2020-03-31 | -52.14% |
| 2019-12-31 | -41.48% |
| 2019-09-30 | -50.07% |
| 2019-06-30 | -48.67% |
| 2019-03-31 | -43.83% |
| 2018-12-31 | -56.96% |
| 2018-09-30 | -42.17% |
| 2018-06-30 | -33.51% |
| 2018-03-31 | -22.52% |
| 2017-12-31 | -42.71% |
| 2017-09-30 | -45.21% |
| 2017-06-30 | -39.27% |
| 2017-03-31 | -41.10% |
| 2016-12-31 | -64.80% |
| 2016-09-30 | -94.01% |
| 2016-06-30 | -85.14% |
| 2016-03-31 | -87.94% |
| 2015-12-31 | -92.30% |
| 2015-09-30 | -82.45% |
| 2015-06-30 | -59.88% |
| 2015-03-31 | -72.78% |
| 2014-12-31 | -36.91% |
| 2014-09-30 | -20.63% |
| 2014-06-30 | -19.20% |
| 2014-03-31 | -12.41% |
| 2013-12-31 | -17.78% |
| 2013-09-30 | -74.29% |
| 2012-09-30 | -490.06% |
| 2012-06-30 | -183.69% |
| 2012-03-31 | 4.07% |
| 2011-12-31 | -35.42% |
| 2011-09-30 | 12.85% |
| 2011-06-30 | -19.05% |
| 2011-03-31 | -125.23% |
| 2010-12-31 | -57.36% |
| 2010-09-30 | -34.51% |
| 2010-06-30 | -56.86% |
| 2010-03-31 | -50.59% |
| 2009-12-31 | -144.96% |
| 2009-09-30 | -124.42% |
| 2009-06-30 | -132.04% |
| 2009-03-31 | -331.25% |
| 2008-12-31 | -206.23% |
| 2008-09-30 | -166.72% |
| 2008-06-30 | -149.71% |
| 2008-03-31 | -135.14% |
| 2007-12-31 | -112.83% |
| 2007-09-30 | -79.61% |
| 2007-06-30 | -68.35% |
| 2007-03-31 | -53.39% |
| 2006-12-31 | -112.38% |
| 2006-09-30 | -94.48% |
| 2006-06-30 | -74.96% |
| 2006-03-31 | -68.86% |
| 2005-12-31 | -67.15% |
| 2005-09-30 | -53.69% |
| 2005-06-30 | -75.09% |
| 2005-03-31 | -57.30% |
| 2004-12-31 | -42.63% |
| 2004-09-30 | -35.41% |
| 2004-06-30 | -28.99% |
| 2004-03-31 | -20.24% |
| 2003-12-31 | -20.86% |
| 2003-09-30 | -14.33% |
| 2003-06-30 | -5.10% |
